Sexually Transmitted Diseases

NIAID researchers make an unexpected discovery when examining how a cellular enzyme complex regulates herpesvirus; inhibiting the enzyme suppressed viral infection.

Proton pump inhibitors present risks to all patients, but those with HIV are especially advised to be cautious in using them.

Alex Rinehart, PhD, explains how cabotegravir is a gender-neutral pre-exposure prophylaxis medication.

Dr. Brennan-Ing, ACRIA, shared in a presentation at the 125th Annual Convention of the American Psychological Association that a growing population is being overlooked when it comes to HIV treatment and prevention: older adults.

This week we explore whether or not a national state of emergency and criminalizing opioid abuse will really help to stop the problem.

Researchers from the University of Mississippi report a case of an HIV-positive man with pneumonia due to MRSA who was treated with dalbavancin.

Kenneth Mayer, MD, discusses some societal challenges that at-risk individuals face today that may keep them from taking pre-exposure prophylaxis.

A herpes infection leads to deadly viral meningitis in an Iowa infant, an ingestible smart pill that can remind you to take your medications, global catastrophic biological risks, whether or not you should complete the full course of antibiotics, and all you need to know about Candida auris make up this week’s Top 5 articles.

Reports of increasing cases of antibiotic-resistant gonorrhea are on the rise and in fact, the World Health Organization has designated the infection as high priority as it poses a great public health threat.

Newly diagnosed HIV patients have several options when it comes to notifying partners, but assisted partner notification leads to the best outcomes.

The recent death of an infant in Iowa who got meningitis following exposure to the herpes simplex virus serves as a grim reminder of how dangerous the virus can be for newborns.

Jessica Justman, MD, explains the PHIA Project (population-based HIV impact assessments).

New research on Zika, cases of swine flu infections, parallels between Zika and HIV, a new warning sign of HIV infection, and an increase in cyclospora cayetanensis infections in United States make up the top 5 articles this week.

Researchers from LSU Health New Orleans School of Public Health finds that heterosexuals at-risk for HIV would use home-based testing kits and seek treatment if they receive a positive result.

The risk of mortality is elevated in HIV-positive individuals who have detectable levels of virus 6 months after beginning antiretroviral therapy.

Despite the progress that has been made, more research is needed on cancer prevention, hepatitis B, and human papillomavirus vaccines.

Parallels between the recent Zika epidemic in Brazil and the HIV pandemic in the 1980s, stress the importance of improving responses to public health crises.

Florida reports first case of sexually-transmitted Zika of 2017, while funds continue to be released for new research efforts against the virus and tests to aid in rapid diagnosis.

Hanneke Schuitemaker, PhD, explains what makes Janssen’s new HIV-1 vaccine regimen unique.

Researchers report a case of undiagnosed HIV infection that first presented as necrotizing ulcerative stomatitis.

A recent study takes a closer look at statin use in HIV-positive patients who are taking protease inhibitors.

New HIV drugs, vaccine regulations in France, correlations between intestinal viruses & type 1 diabetes, the susceptibility of Florida mosquitoes to transmit chikungunya, and an evaluation of the risk of hepatitis B reactivation in veterans on direct-acting antiviral therapy make up our Top 5 articles for the week of July 30, 2017.

A recent study showed that most migrants to European countries acquired their HIV infections in their host countries, particularly those from Latin America and the Caribbean.

Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains what makes cabotegravir a unique medication for HIV.

Kenneth Mayer, MD, explains why primary care providers need to have a good sense of their patients in order to help them decide if PrEP is right for them.